Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)
Authors:
- 10 November 2005
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (1) , 121-129
Abstract
Aims: The aim of this study was to determine the mean costs and outcomes associated with modifiable risk factors in patients with type 2 diabetes and to determine equivalent changes to these risk factors in terms of financial costs and health outcomes.Methods: The Cardiff Stochastic Simulation Cost-Utility Model (DiabForecaster), which evolved from the Eastman model, was used to follow a cohort of 10 000 patients over 20 years.Results: Costs were affected most significantly by changes in the total cholesterol to HDL cholesterol (Total‐C:HDL‐C) ratio and in HbA1c. Unit increases in Total‐C:HDL‐C increased discounted costs by £200 per patient; for ratios > 8 units, unit increases led to cost increases of £300 per patient. Unit increases in HbA1c increased per patient discounted costs from £200 (5–6%) up to £2900 (10–11%). Similar patterns were observed for QALYs. Estimates of equivalence showed that a 1% reduction in HbA1c was equivalent to an 0.4 increment in QALYs, which was equivalent to a reduct...Keywords
This publication has 14 references indexed in Scilit:
- The Routine Collation of Health Outcomes Data from Hospital Treated Subjects in the Health Outcomes Data Repository (HODaR): Descriptive Analysis from the First 20,000 SubjectsValue in Health, 2005
- The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complicationsDiabetes Research and Clinical Practice, 2005
- Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debateDiabetes, Obesity and Metabolism, 2004
- The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)Diabetic Medicine, 2003
- UKPDS 60Stroke, 2002
- Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 DiabetesJAMA, 2002
- An economic model of the long-term health care burden of Type II diabetesDiabetologia, 2001
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Epidemiology and costs of acute hospital care for cerebrovascular disease in diabetic and nondiabetic populations.Stroke, 1997
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991